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Objectives: We hypothesised that stress echocardiography (SE), may be superior to exercise ECG (ExECG), for
predictingCADandoutcome, and cost-beneﬁcial,whenperformedas initial investigation innewly suspected angina.
Methods: All patients seen in 2011, with suspected angina, no history of CAD, pre-test likelihood of CAD of N10%
andwho underwent SE or ExECG as ﬁrst line were identiﬁed retrospectively. Cost to diagnosis was calculated by
adding the cost of all tests, up to and including coronary angiography (CA), on an intention-to-treat basis. Follow-
up data on cardiac death andmyocardial infarction (MI) were collected, 26months after the presentation of the
last study patient.
Results:A total of 456 patients underwent ExECG (224 (49%) negative, 93 (20%) positive, 139 (31%) inconclusive)
and 241 underwent SE (200 (83%) negative, 35 (15%) positive, 6 (2%) inconclusive) as ﬁrst line. In patients
subsequently undergoing CA, CAD was present in 46% (37/80) of patients with positive ExECG vs. 72% (23/32)
patients with positive SE (p = 0.01). Mean cost to diagnosis was £456 for the ExECG vs. £360 for the SE group
(p = 0.002). Over a mean follow-up period of 31 ± 5 months, cardiac events were 2% each in negative SE vs.
negative ExECG (p = 0.9).
Conclusions: SE is superior to ExECG for prediction of CAD and is cost-beneﬁcial when used as initial test in
patients with no history of CAD presenting with suspected angina.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients presenting with chest pain account for over 500,000 outpa-
tient appointments per year in the UK with an estimated cost to the
National Health Service of around £52 million [1]. Most hospitals in the
UK offer a form of Rapid Access Chest Pain Clinic (RACPC) service, with
the intention to evaluate whether these patients suffer from coronary ar-
tery disease (CAD). Diagnostic testing is recommended for themajority of
these patients, with the exception of those with the lowest (b10%) pre-
test probability of CAD [2]. Due to perceived cost implications, Exercise
electrocardiogram (ExECG) is still widely used in the UK and Europe as
the ﬁrst test, and is the initial test of choice in the US in patients with nor-
mal baseline ECG, who can exercise [3]. Stress echocardiography (SE) is ayal Brompton Hospital, Sydney
+44 2073518604.
enior).
nd Ltd. This is an open access article unwell-established alternative technique, used for the assessment of CAD.
The advent of tissue harmonic imaging, digital image acquisition and,
lately, trans-pulmonary echo-contrast agents have all led to improved
image quality, feasibility, reproducibility and accuracy of SE [4–6].
A previous study has indicated that SE is more cost-effective than
ExECG for the risk stratiﬁcation of patients presenting with suspected
acute coronary syndrome [7]. Another large study has also previously
shown superior cost-effectiveness of SE compared to ExECG in patients
with stable angina who are able to exercise [8]. However this latter
study included patients with pre-existing CAD, making up 25% of the
study population. There is therefore, so far, no data comparing, in a
real world setting, SE, including contemporary techniques, to ExECG,
in patients, presenting with new-onset suspected stable angina,
irrespective of exercise capacity. This population is of particular clinical
and economic interest, as it comprises the majority of patients with
newly suspected CAD. We thus hypothesised, that SE by virtue of its
superior feasibility and accuracy, may be superior to ExECG, both forder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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initial test for the evaluation of patients with no previous history of
CAD who present with suspected stable angina.
2. Methods
2.1. Study design
A retrospective analysis of all patients seen in the RACPC of our local
hospital during 2011 was performed. Information was collected from
electronic hospital records with regard to the initial clinic attendance
and any subsequent cardiac investigations. The study was approved by
our local research department. Patients who presented with new onset
chest pain,with noprevious history of CADandwith apre-test probability
of CAD of N10%, who underwent SE or ExECG as the initial investigation
were identiﬁed. We excluded patients with unstable angina, deﬁned as
rest chest pain of more than 10 min, onset of angina within two months
with crescendo pattern andwith signiﬁcant resting ST-T changes. The de-
cision to undergo either test wasmade by the attending clinician andwas
dependent on factors such as the presence of resting ECG changes ormed-
ical comorbidities that may have made a patient unsuitable for ExECG
(e.g. LBBB, chronic respiratory disease,mobility issues) and on the depart-
mental availability of ExECG or SE slots. Patients would generally undergo
a resting ECG but not a resting echocardiogram, as a routine, prior to the
functional test. Patients with a known history of ischaemic heart disease
based on previous myocardial infarction, previous coronary
revascularisation (coronary angioplasty or cardiac surgery), or evidence
of ﬂow limiting CAD on previous angiography, were excluded from
further analysis. The pre-test probability of CAD was calculated for
each individual patient based on the description of the documented
symptoms and the presence of risk factors using the algorithm
from NICE guidelines [2,9]. For the purposes of the study, the post-
test probability of CAD was deemed to be high in cases with a
positive functional test, low in cases with a negative functional test
and intermediate in cases with an inconclusive functional test.
2.2. Exercise ECG
Patients underwent ExECG using the standard Bruce protocol
treadmill testing. Endpoints were fatigue, severe ischaemia (severe
chest pain, N2 mm ST depression), severe hypertension (systolic
BP N 220 mm Hg), hypotension (systolic BP b 90 mm Hg), pre-
syncope or arrhythmia. Patients who achieved a work-load of ≥9
METS or achieved 85% of target heart rate, without any symptoms, hae-
modynamic compromise or ECG changes were considered to have a
negative test. Patients, who developed signiﬁcant chest pain, hypoten-
sion, arrhythmia, or ≥1 mm planar or down-sloping ST depression in
two or more leads of the same territory, during exercise or in recovery,
were considered to have a positive test. All other patients were consid-
ered to have an inconclusive test. ExECG were performed by cardiac
physiologists and interpreted by the attending clinicians.
2.3. Stress echocardiography
Patients underwent SE using either treadmill or pharmacological
testing at the discretion of the cardiologist performing the test as per
departmental protocol [7]. A two-dimensional echocardiogram was
performed in the lateral decubitus position. Digital images, with tissue
harmonic imaging, of the left ventricle (LV) were obtained in the
parasternal long-axis, short-axis and apical, four-, two- and three-
chamber views using an IE33 echocardiography system with an S5
probe (Philips, Best, Netherlands). Exercise stress echocardiography
(ESE) was performed using the standard symptom-limited treadmill
exercise protocol, with images acquired immediately (within 90 s)
after peak exercise. In patients whowere deemed unsuitable for exercise
testing, dobutamine was infused peripherally in 3 min dose increments,starting from 10 μg/kg/min and increased to 20, 30 and 40 μg/kg/min. If
no end-point was reached, atropine was added to the continuing
dobutamine infusion, up to a maximum of 1.2 mg. Endpoints were the
achievement of 85% of age-predictedmaximumheart rate; development
of ischaemia; achievement of peak dose; or the occurrence of intolerable
side-effects. Peak stress or immediate post-exercise imageswith the best
endocardial deﬁnition were selected and displayed alongside the corre-
sponding baseline images. In technically difﬁcult patients (when two
or more segments were not adequately visualised at rest), intravenous
contrast (Sonovue, Bracco, Italy) was used to enhance endocardial bor-
der deﬁnition. Bolus injections of 0.3–0.5 ml were administered through
a peripheral cannula followed by a ﬂush with 0.9% NaCl solution.
2.4. Image analysis
On-line digital imageswere interpreted qualitatively for the presence,
extent and location of segmental wall motion abnormality (WMA). An
experienced operator (RS) analysed the images for systolic wall thicken-
ing and endocardial wall motion according to a four-point score (1:
Normal; 2: Hypokinetic; 3: Akinetic; 4: Dyskinetic motion) using a 17-
segment left ventricle (LV)model. The stress echocardiogramwas consid-
ered negative if all segments were normal at baseline and peak stress.
Patients with evidence of WMA at rest or development of regional
WMA at peak stress were deemed to have a positive stress echocardio-
gram. Patients with un-interpretable images or patients that failed to
achieve the target heart ratewere considered to have an inconclusive test.
2.5. Coronary angiography
The decision to perform coronary angiography was taken at the
discretion of the attending clinician with knowledge of the non-invasive
test results. Standard techniques were used for performing the angio-
gram. Images were analysed using a visual quantitative scoring system,
with CAD deﬁned as N50% luminal diameter narrowing in one or more
epicardial coronary arteries or their major branches. The cut-off value of
50% was used as it has been previously shown to convey prognostic
signiﬁcance [10].
2.6. Cost analysis
The cost analysis was performed using data from the NHS resource
tariff of 2011–2012 [11]. Resource use data was collected for all patients
on an intention-to-treat basis. We took into account cases where inves-
tigations were performed as well as cases where investigations were
requested but were not performed due to patients not attending. Cost
to diagnosis was deﬁned as the sum of all investigations performed up
to and including the point when diagnosis or presumed absence of
CAD was deemed established. These included a diagnostic CA, a nega-
tive functional test or a decision not to proceed with any further tests.
2.7. Follow up
Data was collected by means of electronic searches of the hospital
databases and the NHS registry. Follow-up time was calculated from
the day of the initial test to either the date of the cardiac event or the
date the database search was performed. Cardiac death was deﬁned as
death associated with known or suspected myocardial infarction (MI),
life threatening cardiac arrhythmia (VT or VF) or heart failure based
on clinical assessment, serum cardiac markers (Troponin I), ECG or
cause of death listed on national registry. Non-fatal MI was deﬁned
according to established criteria [12]. Coronary revascularisation was
deﬁned as percutaneous coronary intervention (PCI) or coronary artery
bypass grafting (CABG). Follow-up assessment was performed by a
research technician, who was blinded to the study group.
Table 1
Baseline characteristics.
ExECG SE p value
Patient demography
N 456 257
Age 56 (±11.3) 64 (±11.4) b0.001
Male 36% 58% b0.001
Cardiac risk factors
Diabetes 19% 26% 0.02
Cholesterol N6.47 mmol 22% 21% 0.8
Smoking 16% 10% 0.03
Pre-test probability of CAD
10–30 (low) 43% (198) 30% (77)
30–60 (intermediate) 29% (132) 33% (85)
N60 (high) 28% (126) 37% (95)
Mean score 43 (±26) 51 (±28) b0.001
126 K. Zacharias et al. / IJC Heart & Vasculature 7 (2015) 124–1302.8. Statistical analysis
Continuous variables are shown asmean± SD. Categorical variables
are shown as proportions. Comparison of continuous data wasmade by
independent t-test. To compare the proportion of categorical variables,
Pearson's χ2 test was used. The Net Reclassiﬁcation Improvement
(NRI) and the Integrative Discrimination Index (IDI) were used to com-
pare how ExECG and SE reclassify the risk of CAD in patients with respect
to the original NICE risk score [13]. Survival curve analysis to compare
event rates in the ExECG versus SE group was made using log-rank
testing. For all statistical tests, a p value of b0.05 was considered signiﬁ-
cant. Statistical analyses were performed using SPSS Statistics version
21.0 (IBM Software). The NRI and IDI were computed using R statistical
software (R Foundation for Statistical Computing, Vienna).
3. Results
The ﬂow of patients from the initial assessment through to ExECG and
SE is shown in Fig. 1. The characteristics of patients referred to undergo
ExECG vs. SE are shown in Table 1. Patients referred for SE were signiﬁ-
cantly older and had a higher prevalence of male gender and diabetes.
This translated into a higher pre-test probability of CAD in the SE com-
pared to the ExECG group. Fig. 2 depicts the ﬂow of patients from the ini-
tial ExECG or SE results through to further requested tests or discharge.
3.1. Exercise ECG
All patients, who were referred for an ExECG, underwent the test on
the same day as their clinical assessment. Reasons for an inconclusive
ExECG were insufﬁcient workload in 61 (44%), presence of borderline
ECG changes with no symptoms in 25 (18%) and development of non-
limiting symptoms (dyspnoea, chest discomfort) with no ECG changes
in 53 (38%) patients. Of the 224 patients who had a negative ExECG,
diagnostic doubt persisted, in the opinion of the clinician, in 10 patients
whowere referred for a further SE. One further patient was incidentally
diagnosed with signiﬁcant valve pathology, and was referred for CA as
part of a pre-operative work-up. Of the 93 patients with a positive
ExECG, 86 were referred directly for CA. The remaining 7 patients
were referred for a SE as they were initially reluctant to undergo CA.
Twopatients in this latter group had a positive SE andwere subsequent-
ly referred for CA. Of the 139 patients with an inconclusive ExECG, 104Fig. 1. Flow of patients frompresentation to initial test (ExECGor SE). RACPC: Rapid Access Chespatients were referred for a SE. In the latter group, 10 patients were
subsequently referred for a CA.3.2. Stress echocardiography
SE was performed as the initial investigation in 241 patients, while
16 patients failed to attend their scheduled appointment on two separate
occasions and were therefore discharged. Of the 241 patients who
underwent a SE, 8 (3%) had no stress testing as the baseline echocardio-
gram demonstrated regional wall motion abnormality, or signiﬁcant
valve pathology that was not previously known. Of the remaining 233
patients, 99 (41%) and 134 (56%) patients underwent exercise SE and
dobutamine SE respectively. Trans-pulmonary echo-contrast agent was
used in 154 (64%) of patients. All 200 patients with a negative test were
discharged from the clinic with no further investigations. Coronary
angiography was requested in 34 patients with a positive SE. In the
one remaining case, the area of ischaemia on SE was considered to be
very limited and as such the patient was considered low risk and was
treated with medical therapy. Of the 6 patients with an inconclusive
SE, one was deemed to suffer from hypertensive heart disease and
was treated medically, two were referred for coronary angiography
and the remaining three patientswere referred for a nuclearmyocardial
perfusion scan.t Pain Clinic, CAD: coronary artery disease, ExECG: exercise ECG, SE: stress echocardiogram.
Fig. 2. Flow of patients from initial ExECG or SE through to further requested tests or discharge. CA: coronary angiogram, MPS: myocardial perfusion scan).
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Following testing, signiﬁcantly (p b 0.01) more patients in the SE
group (83%) were classiﬁed as low risk (negative test) compared to
the ExECG group where only 49% were classiﬁed as low risk. In the
ExECG group, signiﬁcantly (p b 0.01) more patients (31%) were classi-
ﬁed as inconclusive vs. only 2% in the SE group. Finally, a signiﬁcantly
(p = 0.03) greater proportion of patients in the ExECG group (20%)
had a high post-test risk (positive test) vs. in the SE group (15%). The
risk stratiﬁcation of patients, pre and post-test in the ExECG and the
SE groups, is shown in Table 2. A signiﬁcantly greater proportion of
patients (NRI: 72%) were appropriately reclassiﬁed using SE with
respect to CAD risk compared to ExECG (NRI: 55%) (p b 0.01). In both
groups the reclassiﬁcation occurred in non-borderline cases, that isTable 2
Pre and post test probability of CAD.
Stress echocardiogram Pre-test Post test
High Intermediate Low
High 23 3 64
Intermediate 7 3 69
Low 5 0 67
Exercise ECG Pre-test Post test
High Intermediate Low
High 48 42 36
Intermediate 26 36 70
Low 19 61 118either from low to high or fromhigh to low risk groupswith a signiﬁcant-
ly higher IDI for SE (35%) versus ExECG (23%) (p b 0.01).
3.4. Further investigations in SE vs. ExECG groups
In total, 273/713 patients required further testing, after the initial non-
invasive tests, in order to either conﬁrm or dismiss the diagnosis of CAD.
There was a signiﬁcantly (p b 0.0001) higher proportion of these patients
in the ExECG group (234/456, 51%) compared to the SE group (39/257,
15%). A total of 36 angiogramswere requested inpatientswhounderwent
a SE as opposed to 124 angiograms that were requested in patients who
underwent ExECG as ﬁrst line investigations respectively. The breakdown
of further investigations required in each group is shown in Table 3.
3.5. CAD and revascularisation
Of the 32 out of the 34 patients with a positive SE who underwent
coronary angiography, 23 patients (72%) had CAD on angiography. OfTable 3
Downstream investigations.
ExECG SE
Stress echocardiogram 121 0
Myocardial perfusion scan 1 3




Test Unit cost (£) Number of tests
ExECG SE
Initial ExECG 114 456 0
Initial SE 200 0 257
Subsequent SE 200 121 0
Myocardial perfusion scan 280 1 3
Coronary angiogram 1052 124 36
Echo contrast 15 69 154
Total cost 207,947 92,422
Mean cost 456 360
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procedure and CAD was identiﬁed in 37 patients (46%). Thus the posi-
tive predictive value (PPV) of SE was signiﬁcantly (p = 0.01) higher
than that of ExECG.
Patientswith a positive SE had a higher prevalence ofmulti-vessel dis-
ease (48% vs. 32%) and were more likely to undergo CABG (54% vs. 29%)
compared to patientswith a positive ExECG. The overall revascularisation
rate, within a year, in patients with positive tests was 37% vs. 30% respec-
tively. No statistical differencewas shown, probably because of the overall
small sample size. The remaining patients, with CAD on angiography,
either declined revascularisation or were deemed to be unsuitable for
revascularization, based on their overall clinical condition and coro-
nary anatomy, andwere therefore treatedwithmedical therapy. The
revascularisation strategies used in each group are shown in Table 4.
3.6. Cost to diagnosis of CAD
The total use of resources and unit costs for the two groups is shown
in Table 5. The overall mean cost to diagnosis on an intention to treat
basis was £456 for the ExECG group, which was signiﬁcantly (p =
0.002) higher than that in the SE group which was £360. The mean
cost to diagnosis for patients was lower for patients undergoing SE as
ﬁrst line, in all pre-test probability of CAD categories, reaching statistical
signiﬁcance in the intermediate (p = 0.02) and high (p = 0.002) risk
groups. This is depicted in Table 6.
3.7. Follow up
Follow-up was performed at a mean of 31± 5months. A total of six
deaths occurred in that period in the whole study population. Five of
these deaths were non-cardiac with the causes of death listed as lung
malignancy in two cases, acute leukaemia, alcoholic liver disease and
community-acquired pneumonia. One death occurred in a patient
who initially underwent an ExECG, deemed inconclusive, subsequent
SE showing functional ischaemia and three-vessel disease conﬁrmed
on angiography. The patient died at home, after declining the offer for
revascularisation, from a presumed cardiac event.
No cardiac deaths occurred in patients who were discharged on the
basis of either a negative ExECG or negative SE. There were 9 patients
who suffered an MI with 5 (2.2%) out of 224 in patients with an initial
negative ExECG (1.0%/year) and 4 (2%) out of 200 patients with an
initial negative SE (0.9%/year). There was no signiﬁcant difference
between event rate in these two groups (p = 0.9 by log rank test). No
patients in the positive ExECG group suffered an MI versus 2 patients
with a subsequent MI in the positive SE group. Fig. 3 shows the
Kaplan–Meier survival curve analysis of hard cardiac events (cardiac
death, non-fatal MI) in patients deemed to have a low post-test risk
(negative tests).Table 4
Revascularisation.
ExECG SE p value
Total number of patients 456 257
Positive tests 93 35
Underwent angiogram 80 32
CAD on angiogram 37/80 (46%) 23/32 (72%) 0.01
Number of vessels 1 2 3 1 2 3
Number of patients 25 7 5 12 6 5
Percentage of patients 68% 19% 13% 52% 26% 22%
Revascularisation 28/93 (30%) 13/35 (37%) 0.4
PCI 20 6
Number of vessels 1 2 3 1 2 3
Number of patients 16 4 0 5 1 0
CABG 8 7
Number of vessels 1 2 3 1 2 3
Number of patients 1 2 5 1 1 54. Discussion
This is the ﬁrst study to compare directly, initial SE versus initial
ExECG strategies in consecutive patients, irrespective of their exercise
capacity, presenting to a Rapid Access Chest Pain Clinic, with symptoms
suggestive of stable angina but no previous history of CAD. SEwas supe-
rior to ExECG for the prediction of CAD as assessed by invasive coronary
angiography in patients with a positive test, with no difference inmedi-
um term outcome in patients whose initial tests were negative (hard
cardiac events in SE group b1%/year).
Moreover, SE re-classiﬁed a signiﬁcantly higher proportion of
patients as low risk compared to ExECG, despite patients having a
higher pre-test probability of CAD in the SE group. This is further sup-
ported by NRI analysis. Conversely, a signiﬁcant proportion of patients
in the ExECG group were re-classiﬁed as having an intermediate risk,
due to the high percentage of ExECG tests deemed inconclusive. This
resulted in more downstream investigations in the ExECG group vs. SE
group, for establishing or refuting the diagnosis of CAD. Consequently,
the higher initial cost of SE vs. ExECGwas off-set by a lower requirement
for additional investigations and thus the ultimate cost to diagnosis of
CAD was lower in the SE group across all pre-test probability of CAD
groups. It is important to note that the cost analysis performed is
based on previously acceptedmethodology [7] and on the national tariff
corresponding to the year of the study [11], rather than cost estimates.
Moreover, although patients in the SE group have a higher pre-test
probability than those in the ExECG group, the use of downstream in-
vestigations is much lower in the SE group. One would expect that if
the two groups were matched at baseline, the overall cost difference
in favour of SE would increase. The use of the NRI, which has been sug-
gested as a method that can account for differences at baseline [13],
supports this hypothesis. This study therefore highlights the superior
value of initial SE strategy compared to initial ExECG strategy in patients
presenting with angina symptoms and with no previous history of CAD
in a real world clinical setting, in all pre-test probability of CAD
categories.
A large previous study that assessed cost-effectiveness of SE vs.
ExECG in patients with and without known stable CAD collectively
showed that SE was more cost-effective than ExECG [8]. However, this
study included patients with known CAD and only included patients
who could exercise. Furthermore patients were not classiﬁed according
to pre-test probability of CAD (probably because of inclusion of known
CAD patients), contrary to standard practice today. Another study
from our group compared these two stress techniques but in patientsTable 6
Cost of diagnosis per risk-category.
Initial test Cost of diagnosis (£) p value
ExECG SE
Pre-test risk
Low (10–30) 340 278 0.1
Intermediate (30–60) 412 301 0.02
High (N60) 685 478 0.002
Fig. 3. Kaplan–Meier survival curve analysis in low post-test risk patients in SE vs.
ExECG groups.
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that showed very similar results to the present, retrospective study,
whichwas however performed in patientswith suspected stable angina
[7].
It is interesting to note that studies comparing SPECT to ExECG in
stable chest pain patients have not shown any cost-savings [14,15]. In
a randomised study, where the group of patients was similar to the
present study, the cost to diagnosis in the SPECT arm was similar to
that in the ExECG arm but was higher in the low pre-test probability
of CAD group [14]. In another study where Exercise SPECT was com-
pared to ExECG in women with stable chest pain, an initial strategy of
ExECG was more cost-effective than ExSPECT [15]. These two studies
formed the basis for the guidelines by ACC/AHA to confer ExECG as
the ﬁrst line investigation of patients who can exercise and have an
interpretable ECG [3]. The recent ESC guidelines also endorsed this
strategy but with a caveat that only if stress imaging is not available [16].
It is clear from the present and from previous nuclear perfusion
imaging studies in a very similar population that ExECG is less accurate
than stress imaging for the diagnosis of CAD and that this results in a
higher number of downstream investigations and in possible patient-
anxiety. In the present study, 80% of patientswere reassuredwith a neg-
ative SE study compared to only 50% when patients underwent ExECG.
However, nuclear imaging studies did not show a cost advantage
compared to ExECG. On the other hand, SE demonstrated cost–beneﬁt
compared to ExECG. The major reason for the cost advantage of SE is a
lower initial cost compared to nuclear imaging. In addition, SE does
not involve ionising radiation, can be more rapidly performed with
immediate results and can be more ubiquitously available. These attri-
butes of SE should make this technique the preferred method of testing
for ischaemia in this population in rapid access one-stop chest pain clinics.
4.1. Study limitations
In this retrospective service evaluation, patients were not allocated
to each group in a randomised fashion but rather according to our
regular clinical practice and consequently the pre-test probability of
patients in the SE group was higher than that in the ExECG group.
Even so however, a much greater percentage of patients in the SE
group were reclassiﬁed post-test as low risk. As part of the serviceevaluation process, follow-up data was collected by hospital records
rather than direct patient contact. It is therefore conceivable that patients
who suffered a cardiac event in another centre and had no further atten-
dance in our unit may have beenmissed. However, by limiting follow-up
to hard events such as death and non-fatal MI, which could be veriﬁed by
cross-referencing with the national registry and our pathology laborato-
ries, we are conﬁdent that the outcome data is robust.
In our study, CADwas considered to bepresentwhen N50% diameter
stenosis was seen on coronary angiography. This cut-off value has been
shown to be of prognostic signiﬁcance [10] and is currently used in the
ongoing large multicentre ISCHEMIA trial as a cut-off to deﬁne obstruc-
tive CAD [17]. The PPV of SEwas superior to that of ExECG for the detec-
tion of CAD as deﬁned above. There was also a trend towards greater
detection of multi-vessel disease, higher rates of CABG and overall
revascularisation rate with a positive SE although the sample size was
not large enough for statistical signiﬁcance to be established. Patients
who did not undergo revascularisation however, were still likely to
beneﬁt from optimal medical therapy for CAD including aspirin, statin
and anti-anginal medications. This study suggests that a randomised
prospective study comparing the use of ExECG against SE is warranted.
5. Conclusion
In this retrospective study comparing the use of SE to ExECG in a
real-world clinical setting, SE was superior to ExECG in predicting CAD
andwas cost-beneﬁcialwhen used as the initial investigation in patients
with no previous history of CAD presentingwith new suspected angina.
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